CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
2019 | 2020 | 2021 | ||||||||||||||||||||||||||
(in millions) | Mar 31 | Jun 30 | Sep 30 | Dec 31 | Mar 31 | Jun 30 | Sep 30 | Dec 31 | Mar 31 | Jun 30 | ||||||||||||||||||
Assets | $ | 30,125 | $ | 30,234 | $ | 25,051 | $ | 24,314 | $ 21,190 | $ | 26,049 | $ | 6,245 | $ | 7,361 | |||||||||||||
Cash, cash equivalents and marketable securities | $ | 25,840 | $ | 7,910 | ||||||||||||||||||||||||
Accounts receivable, net | 3,283 | 3,396 | 3,315 | 3,582 | 3,907 | 3,194 | 3,913 | 4,892 | 3,925 | 4,149 | ||||||||||||||||||
Inventories | 898 | 884 | 882 | 2,067 | 2,021 | 1,967 | 1,953 | 3,014 | 2,996 | 2,988 | ||||||||||||||||||
Property, plant and equipment, net | 4,116 | 4,249 | 4,377 | 4,502 | 4,564 | 4,653 | 4,810 | 4,967 | 4,990 | 4,996 | ||||||||||||||||||
Intangible assets, net | 15,438 | 15,152 | 14,864 | 13,786 | 13,502 | 13,225 | 12,939 | 33,126 | 34,781 | 34,341 | ||||||||||||||||||
Goodwill | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 8,108 | 8,334 | 8,334 | ||||||||||||||||||
Other assets | 4,860 | 5,178 | 6,540 | 7,733 | 7,316 | 7,588 | 7,097 | 6,390 | 6,221 | 5,815 | ||||||||||||||||||
Total assets | $ | 62,837 | $ | 63,210 | $ | 59,146 | $ | 61,627 | $ | 59,741 | $ 55,934 | $ | 60,878 | $ | 68,407 | $ | 67,492 | $ | 67,984 | |||||||||
Liabilities and Stockholders' Equity | ||||||||||||||||||||||||||||
Current liabilities | $ | 9,397 | $ | 8,961 | $ | 9,567 | $ | 9,759 | $ | 8,879 | $ 10,564 | $ | 9,509 | $ | 11,397 | $ | 9,705 | $ | 10,214 | |||||||||
Long‐term liabilities | 31,349 | 31,498 | 28,843 | 29,218 | 28,683 | 27,228 | 33,898 | 38,789 | 38,823 | 38,060 | ||||||||||||||||||
Stockholders' equity | 22,091 | 22,751 | 20,736 | 22,650 | 22,179 | 18,142 | 17,471 | 18,221 | 18,964 | 19,710 | ||||||||||||||||||
Total liabilities and stockholders' equity | $ | 62,837 | $ | 63,210 | $ | 59,146 | $ | 61,627 | $ | 59,741 | $ 55,934 | $ | 60,878 | $ | 68,407 | $ | 67,492 | $ | 67,984 |
Questions? Contact Investor_Relations@gilead.com | 1 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ‐ GAAP
(unaudited)
(in millions, except per share amounts) | 2019 | 2020 | 2021 | ||||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | FY19 | Q1 | Q2 | Q3 | Q4 | FY20 | Q1 | Q2 | ||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||
Product sales | $ | 5,200 | $ | 5,607 | $ | 5,516 | $ | 5,796 | $ | 22,119 | $ | 5,467 | $ | 5,067 | $ | 6,493 | $ | 7,328 | $ | 24,355 | $ | 6,340 | $ | 6,152 | |||||||||||
Royalty, contract and other revenues | 81 | 78 | 88 | 83 | 330 | 81 | 76 | 84 | 93 | 334 | 83 | 65 | |||||||||||||||||||||||
Total revenues | 5,281 | 5,685 | 5,604 | 5,879 | 22,449 | 5,548 | 5,143 | 6,577 | 7,421 | 24,689 | 6,423 | 6,217 | |||||||||||||||||||||||
Costs and expenses: | |||||||||||||||||||||||||||||||||||
Cost of goods sold | 957 | 1,000 | 1,035 | 1,683 | 4,675 | 969 | 1,064 | 1,141 | 1,398 | 4,572 | 1,361 | 1,390 | |||||||||||||||||||||||
Research and development expenses | 931 | 995 | 1,030 | 1,099 | 4,055 | 1,004 | 1,299 | 1,158 | 1,578 | 5,039 | 1,055 | 1,134 | |||||||||||||||||||||||
Acquired in‐process research and development expenses | 126 | 165 | 3,960 | 800 | 5,051 | 97 | 4,524 | 1,171 | 64 | 5,856 | 62 | 96 | |||||||||||||||||||||||
Selling, general and administrative expenses | 1,030 | 1,095 | 1,052 | 1,204 | 4,381 | 1,076 | 1,239 | 1,106 | 1,730 | 5,151 | 1,055 | 1,351 | |||||||||||||||||||||||
Total costs and expenses | 3,044 | 3,255 | 7,077 | 4,786 | 18,162 | 3,146 | 8,126 | 4,576 | 4,770 | 20,618 | 3,533 | 3,971 | |||||||||||||||||||||||
Income (loss) from operations | 2,237 | 2,430 | (1,473) | 1,093 | 4,287 | 2,402 | (2,983) | 2,001 | 2,651 | 4,071 | 2,890 | 2,246 | |||||||||||||||||||||||
Interest expense | (254) | (248) | (250) | (243) | (995) | (241) | (240) | (236) | (267) | (984) | (257) | (256) | |||||||||||||||||||||||
Other income (expense), net | 367 | 228 | 222 | 1,051 | 1,868 | (158) | 250 | (940) | (570) | (1,418) | (369) | (173) | |||||||||||||||||||||||
Income (loss) before income taxes | 2,350 | 2,410 | (1,501) | 1,901 | 5,160 | 2,003 | (2,973) | 825 | 1,814 | 1,669 | 2,264 | 1,817 | |||||||||||||||||||||||
Income tax (expense) benefit | (382) | (535) | 333 | 788 | 204 | (465) | (373) | (472) | (270) | (1,580) | (542) | (300) | |||||||||||||||||||||||
Net income (loss) | 1,968 | 1,875 | (1,168) | 2,689 | 5,364 | 1,538 | (3,346) | 353 | 1,544 | 89 | 1,722 | 1,517 | |||||||||||||||||||||||
Net loss attributable to noncontrolling interest | 7 | 5 | 3 | 7 | 22 | 13 | 7 | 7 | 7 | 34 | 7 | 5 | |||||||||||||||||||||||
Net income (loss) attributable to Gilead | $ | 1,975 | $ | 1,880 | $ | (1,165) | $ | 2,696 | $ | 5,386 | $ | 1,551 | $ | (3,339) | $ | 360 | $ | 1,551 | $ | 123 | $ | 1,729 | $ | 1,522 | |||||||||||
Net income (loss) per share attributable to Gilead common | $ | 1.24 | $ | 0.10 | $ | 1.38 | $ | 1.21 | |||||||||||||||||||||||||||
stockholders ‐ basic | $ | 1.55 | $ | 1.48 | $ | (0.92) | $ | 2.13 | $ | 4.24 | $ | 1.23 | $ | (2.66) | $ | 0.29 | |||||||||||||||||||
Shares used in per share calculation ‐ basic | 1,276 | 1,270 | 1,267 | 1,266 | 1,270 | 1,262 | 1,255 | 1,255 | 1,255 | 1,257 | 1,256 | 1,255 | |||||||||||||||||||||||
Net income (loss) per share attributable to Gilead common | |||||||||||||||||||||||||||||||||||
stockholders ‐ diluted | $ | 1.54 | $ | 1.47 | $ | (0.92) | $ | 2.12 | $ | 4.22 | $ | 1.22 | $ | (2.66) | $ | 0.29 | $ | 1.23 | $ | 0.10 | $ | 1.37 | $ | 1.21 | |||||||||||
Shares used in per share calculation ‐ diluted | 1,283 | 1,277 | 1,267 | 1,273 | 1,277 | 1,270 | 1,255 | 1,261 | 1,259 | 1,263 | 1,262 | 1,260 | |||||||||||||||||||||||
Cash dividends declared per share | $ | 0.63 | $ | 0.63 | $ | 0.63 | $ | 0.63 | $ | 2.52 | $ | 0.68 | $ | 0.68 | $ | 0.68 | $ | 0.68 | $ | 2.72 | $ | 0.71 | $ | 0.71 | |||||||||||
GAAP: | |||||||||||||||||||||||||||||||||||
Product gross margin | 81.6 % | 82.2 % | 81.2 % | 71.0 % | 78.9 % | 82.3 % | 79.0 % | 82.4 % | 80.9 % | 81.2 % | 78.5 % | 77.4 % | |||||||||||||||||||||||
Research and development expenses as a % of revenues | 17.6 % | 17.5 % | 18.4 % | 18.7 % | 18.1 % | 18.1 % | 25.3 % | 17.6 % | 21.3 % | 20.4 % | 16.4 % | 18.2 % | |||||||||||||||||||||||
Acquired in‐process research and development expenses as a % of | |||||||||||||||||||||||||||||||||||
revenues | 2.4 % | 2.9 % | 70.7 % | 13.6 % | 22.5 % | 1.7 % | 88.0 % | 17.8 % | 0.9 % | 23.7 % | 1.0 % | 1.5 % | |||||||||||||||||||||||
Selling, general and administrative expenses as a % of revenues | 19.5 % | 19.3 % | 18.8 % | 20.5 % | 19.5 % | 19.4 % | 24.1 % | 16.8 % | 23.3 % | 20.9 % | 16.4 % | 21.7 % | |||||||||||||||||||||||
Operating expenses as a % of revenues | 39.5 % | 39.7 % | 107.8 % | 52.8 % | 60.1 % | 39.2 % | 137.3 % | 52.2 % | 45.4 % | 65.0 % | 33.8 % | 41.5 % | |||||||||||||||||||||||
Operating margin | 42.4 % | 42.7 % | (26.3)% | 18.6 % | 19.1 % | 43.3 % | (58.0)% | 30.4 % | 35.7 % | 16.5 % | 45.0 % | 36.1 % | |||||||||||||||||||||||
Effective tax rate | 16.3 % | 22.2 % | 22.2 % | (41.5)% | (4.0)% | 23.2 % | (12.5)% | 57.2 % | 14.9 % | 94.7 % | 23.9 % | 16.5 % |
Questions? Contact Investor_Relations@gilead.com | 2 |
SELECTED CASH FLOW INFORMATION
(unaudited)
2019 | 2020 | 2021 | |||||||||||||||||||||||
(in millions) | Q1 | Q2 | Q3 | Q4 | FY19 | Q1 | Q2 | Q3 | Q4 | FY20 | Q1 | Q2 | |||||||||||||
Net cash provided by operating activities | $ 1,577 | $ 2,342 | $ 2,645 | $ 2,580 | $ 9,144 | $ 1,436 | $ 2,566 | $ 2,250 | $ 1,916 | $ | 8,168 | $ 2,610 | $ 2,316 | ||||||||||||
Net cash provided by (used in) investing activities | (244) | (6,163) | (1,841) | 431 | (7,817) | (344) | (5,023) | (271) | (8,977) | (14,615) | (2,042) | (577) | |||||||||||||
Net cash provided by (used in) financing activities | (2,366) | (1,857) | (2,515) | (896) | (7,634) | (2,611) | (874) | 4,124 | 131 | 770 | (2,477) | (931) | |||||||||||||
Effect of exchange rate changes on cash and cash equivalents | 20 | (9) | (55) | 42 | (2) | (61) | 26 | 37 | 41 | 43 | (23) | 20 | |||||||||||||
Net change in cash and cash equivalents | (1,013) | (5,687) | (1,766) | 2,157 | (6,309) | (1,580) | (3,305) | 6,140 | (6,889) | (5,634) | (1,932) | 828 | |||||||||||||
Cash and cash equivalents at beginning of period | 17,940 | 16,927 | 11,240 | 9,474 | 17,940 | 11,631 | 10,051 | 6,746 | 12,886 | 11,631 | 5,997 | 4,065 | |||||||||||||
Cash and cash equivalents at end of period | $ 16,927 | $ 11,240 | $ 9,474 | $ 11,631 | $ 11,631 | $ 10,051 | $ 6,746 | $ 12,886 | $ 5,997 | $ | 5,997 | $ 4,065 | $ 4,893 |
2019 | 2020 | 2021 | |||||||||||||||||||||||||||||
(in millions) | Q1 | Q2 | Q3 | Q4 | FY19 | Q1 | Q2 | Q3 | Q4 | FY20 | Q1 | Q2 | |||||||||||||||||||
Net cash provided by operating activities | $ | 1,577 | $ | 2,342 | $ 2,645 | $ | 2,580 | $ | 9,144 | $ | 1,436 | $ 2,566 | $ | 2,250 | $ 1,916 | $ | 8,168 | $ 2,610 | $ 2,316 | ||||||||||||
Capital expenditures | (237) | (185) | (200) | (203) | (825) | (171) | (143) | (155) | (181) | (650) | (165) | (119) | |||||||||||||||||||
Free cash flow | $ | 1,340 | $ | 2,157 | $ 2,445 | $ | 2,377 | $ | 8,319 | $ | 1,265 | $ 2,423 | $ | 2,095 | $ 1,735 | $ | 7,518 | $ 2,445 | $ 2,197 |
Questions? Contact Investor_Relations@gilead.com | 3 |
NON‐GAAP FINANCIAL INFORMATION(1)
(unaudited)
2019 | 2020 | 2021 | ||||||||||||||||||||||||||||||||||
(in millions, except percentages and per share amounts) | Q1 | Q2 | Q3 | Q4 | FY19 | Q1 | Q2 | Q3 | Q4 | FY20 | Q1 | Q2 | ||||||||||||||||||||||||
Revenues | $ | 5,281 | $ | 5,685 | $ | 5,604 | $ | 5,879 | $ | 22,449 | $ | 5,548 | $ | 5,143 | $ | 6,577 | $ | 7,421 | $ | 24,689 | $ | 6,423 | $ | 6,217 | ||||||||||||
Non‐GAAP: | ||||||||||||||||||||||||||||||||||||
Cost of goods sold | ||||||||||||||||||||||||||||||||||||
$ | 674 | $ | 727 | $ | 769 | $ | 1,417 | $ | 3,587 | $ | 703 | $ | 798 | $ | 875 | $ | 918 | $ | 3,294 | $ | 855 | $ | 836 | |||||||||||||
Research and development expenses | $ | 932 | $ | 996 | $ | 1,028 | $ | 1,103 | $ | 4,059 | $ | 1,004 | $ | 1,186 | $ | 1,155 | $ | 1,512 | $ | 4,857 | $ | 1,049 | $ | 1,084 | ||||||||||||
Selling, general and administrative expenses | $ | 1,030 | $ | 1,096 | $ | 1,045 | $ | 1,204 | $ | 4,375 | $ | 1,076 | $ | 1,164 | $ | 1,095 | $ | 1,499 | $ | 4,834 | $ | 1,033 | $ | 1,121 | ||||||||||||
Operating income | $ | 2,645 | $ | 2,866 | $ | 2,762 | $ | 2,155 | $ | 10,428 | $ | 2,765 | $ | 1,995 | $ | 3,452 | $ | 3,492 | $ | 11,704 | $ | 3,486 | $ | 3,176 | ||||||||||||
Other income (expense), net | $ | 170 | $ | 171 | $ | 164 | $ | 122 | $ | 627 | $ | 125 | $ | 49 | $ | 29 | $ | 46 | $ | 249 | $ | (18) | $ | 1 | ||||||||||||
Net income attributable to Gilead | $ | 2,141 | $ | 2,196 | $ | 2,091 | $ | 1,400 | $ | 7,828 | $ | 2,139 | $ | 1,400 | $ | 2,657 | $ | 2,762 | $ | 8,958 | $ | 2,628 | $ | 2,353 | ||||||||||||
Diluted EPS | $ | 1.67 | $ | 1.72 | $ | 1.64 | $ | 1.10 | $ | 6.13 | $ | 1.68 | $ | 1.11 | $ | 2.11 | $ | 2.19 | $ | 7.09 | $ | 2.08 | $ | 1.87 | ||||||||||||
Shares used in per share calculation ‐ diluted | 1,283 | 1,277 | 1,274 | 1,273 | 1,277 | 1,270 | 1,262 | 1,261 | 1,259 | 1,263 | 1,262 | 1,260 |
Product gross margin
Research and development expenses as a % of revenues Selling, general and administrative expenses as a % of revenues Operating expenses as a % of revenues
Operating margin
Effective tax rate
________________________________
87.0 % | 87.0 % | 86.1 % | 75.6 % | 83.8 % | 87.1 % | 84.3 % | 86.5 % | 87.5 % | 86.5 % | 86.5 % | 86.4 % |
17.6 % | 17.5 % | 18.3 % | 18.8 % | 18.1 % | 18.1 % | 23.1 % | 17.6 % | 20.4 % | 19.7 % | 16.3 % | 17.4 % |
19.5 % | 19.3 % | 18.6 % | 20.5 % | 19.5 % | 19.4 % | 22.6 % | 16.6 % | 20.2 % | 19.6 % | 16.1 % | 18.0 % |
37.2 % | 36.8 % | 37.0 % | 39.2 % | 37.6 % | 37.5 % | 45.7 % | 34.2 % | 40.6 % | 39.3 % | 32.4 % | 35.5 % |
50.1 % | 50.4 % | 49.3 % | 36.7 % | 46.6 % | 49.8 % | 38.8 % | 52.5 % | 47.1 % | 47.4 % | 54.3 % | 51.1 % |
16.6 % | 21.5 % | 22.1 % | 31.5 % | 22.4 % | 19.7 % | 22.8 % | 18.4 % | 15.8 % | 18.6 % | 18.4 % | 19.6 % |
-
Non‐GAAP financial information excludes acquisition‐related expenses including amortization of acquired intangible assets and inventory step‐up charges in Cost of goods sold, acquired IPR&D expenses, and other items that are considered unusual or not
representative of underlying trends of Gilead's business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. A reconciliation between GAAP and non‐GAAP financial information is provided in the tables on pages 5‐6.
Questions? Contact Investor_Relations@gilead.com | 4 |
RECONCILIATION OF GAAP TO NON‐GAAP FINANCIAL INFORMATION
(unaudited)
(in millions, except percentages and per share amounts)
Cost of goods sold reconciliation:
GAAP cost of goods sold
Acquisition‐related - amortization of acquired intangibles and inventory step‐up charges
Acquisition‐related - other costs(1) Non‐GAAP cost of goods sold
Product gross margin reconciliation:
GAAP product gross margin
Acquisition‐related - amortization of acquired intangibles and inventory step‐up charges
Acquisition‐related - other costs(1) Non‐GAAP product gross margin(2)
Research and development expenses reconciliation:
GAAP research and development expenses
Acquisition‐related - other costs(1)
Other(3)
Non‐GAAP research and development expenses
Research and development expenses as a % of revenues:
GAAP research and development expenses as a % of revenues
Acquisition‐related - other costs(1) Other(3)
Non‐GAAP research and development expenses as a % of revenues(2)
Acquired IPR&D expenses reconciliation:
GAAP acquired IPR&D expenses
Acquired IPR&D expenses
Non‐GAAP acquired IPR&D expenses
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses
Acquisition‐related - other costs(1)
Other(3)
Non‐GAAP selling, general and administrative expenses
Selling, general and administrative expenses as a % of revenues:
GAAP selling, general and administrative expenses as a % of revenues
Acquisition‐related - other costs(1) Other(3)
Non‐GAAP selling, general and administrative expenses as a % of revenues(2)
2019 | 2020 | 2021 | ||||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | FY19 | Q1 | Q2 | Q3 | Q4 | FY20 | Q1 | Q2 | |||||||||||||||||||||||
$ | 957 | $ 1,000 | $ 1,035 | $ | 1,683 | $ | 4,675 | $ | 969 | $ 1,064 | $ 1,141 | $ 1,398 | $ | 4,572 | $ 1,361 | $ 1,390 | ||||||||||||||||||
(283) | (273) | (266) | (266) | (1,088) | (266) | (266) | (266) | (417) | (1,215) | (506) | (554) | |||||||||||||||||||||||
‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | (63) | (63) | ‐ | ‐ | |||||||||||||||||||||||
$ | 674 | $ | 727 | $ | 769 | $ | 1,417 | $ | 3,587 | $ | 703 | $ | 798 | $ | 875 | $ | 918 | $ | 3,294 | $ | 855 | $ | 836 | |||||||||||
78.5 % | 77.4 % | |||||||||||||||||||||||||||||||||
81.6 % | 82.2 % | 81.2 % | 71.0 % | 78.9 % | 82.3 % | 79.0 % | 82.4 % | 80.9 % | 81.2 % | |||||||||||||||||||||||||
5.4 % | 4.9 % | 4.8 % | 4.6 % | 4.9 % | 4.9 % | 5.2 % | 4.1 % | 5.7 % | 5.0 % | 8.0 % | 9.0 % | |||||||||||||||||||||||
‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | 0.9 % | 0.3 % | ‐ % | ‐ % | |||||||||||||||||||||||
87.0 % | 87.0 % | 86.1 % | 75.6 % | 83.8 % | 87.1 % | 84.3 % | 86.5 % | 87.5 % | 86.5 % | 86.5 % | 86.4 % | |||||||||||||||||||||||
$ | 931 | $ | 995 | $ 1,030 | $ | 1,099 | $ | 4,055 | $ 1,004 | $ 1,299 | $ 1,158 | $ 1,578 | $ | 5,039 | $ 1,055 | $ 1,134 | ||||||||||||||||||
‐ | ‐ | ‐ | ‐ | ‐ | ‐ | (113) | (3) | (66) | (182) | (6) | (6) | |||||||||||||||||||||||
1 | 1 | (2) | 4 | 4 | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | (44) | |||||||||||||||||||||||
$ | 932 | $ | 996 | $ 1,028 | $ | 1,103 | $ | 4,059 | $ 1,004 | $ 1,186 | $ 1,155 | $ 1,512 | $ | 4,857 | $ 1,049 | $ 1,084 | ||||||||||||||||||
17.6 % | 17.5 % | 18.4 % | 18.7 % | 18.1 % | 25.3 % | 17.6 % | 21.3 % | 16.4 % 18.2 % | ||||||||||||||||||||||||||
18.1 % | 20.4 % | |||||||||||||||||||||||||||||||||
‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | (2.2)% | ‐ % | (0.9)% | (0.7)% | (0.1)% | (0.1)% | |||||||||||||||||||||||
‐ % | ‐ % | ‐ % | 0.1 % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | (0.7)% | |||||||||||||||||||||||
17.6 % | 17.5 % | 18.3 % | 18.8 % | 18.1 % | 18.1 % | 23.1 % | 17.6 % | 20.4 % | 19.7 % | 16.3 % | 17.4 % | |||||||||||||||||||||||
$ | 126 | $ | 165 | $ 3,960 | $ | 800 | $ | 5,051 | $ | 97 | $ 4,524 | $ 1,171 | $ | 64 | $ | 5,856 | $ | 62 | $ | 96 | ||||||||||||||
(126) | (165) | (3,960) | (800) | (5,051) | (97) | (4,524) | (1,171) | (64) | (5,856) | (62) | (96) | |||||||||||||||||||||||
$ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | $ | ‐ | |||||||||||
$ 1,030 | $ 1,095 | $ 1,052 | $ | 1,204 | $ | 4,381 | $ 1,076 | $ 1,239 | $ 1,106 | $ 1,730 | $ | 5,151 | $ 1,055 | $ 1,351 | ||||||||||||||||||||
‐ | ‐ | ‐ | ‐ | ‐ | ‐ | (77) | (12) | (230) | (319) | (22) | (10) | |||||||||||||||||||||||
‐ | 1 | (7) | ‐ | (6) | ‐ | 2 | 1 | (1) | 2 | ‐ | (220) | |||||||||||||||||||||||
$ 1,030 | $ 1,096 | $ 1,045 | $ | 1,204 | $ | 4,375 | $ 1,076 | $ 1,164 | $ 1,095 | $ 1,499 | $ | 4,834 | $ 1,033 | $ 1,121 | ||||||||||||||||||||
19.5 % | 19.3 % | 18.8 % | 20.5 % | 19.5 % | 19.4 % | 24.1 % | 16.8 % | 23.3 % | 20.9 % | 16.4 % 21.7 % | ||||||||||||||||||||||||
‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | (1.5)% | (0.2)% | (3.1)% | (1.3)% | (0.3)% | (0.2)% | |||||||||||||||||||||||
‐ % | ‐ % | (0.1)% | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | ‐ % | (3.5)% | |||||||||||||||||||||||
19.5 % | 19.3 % | 18.6 % | 20.5 % | 19.5 % | 19.4 % | 22.6 % | 16.6 % | 20.2 % | 19.6 % | 16.1 % | 18.0 % |
Questions? Contact Investor_Relations@gilead.com | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Gilead Sciences Inc. published this content on 29 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2021 20:08:07 UTC.